DE3856580D1 - Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein - Google Patents

Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein

Info

Publication number
DE3856580D1
DE3856580D1 DE3856580T DE3856580T DE3856580D1 DE 3856580 D1 DE3856580 D1 DE 3856580D1 DE 3856580 T DE3856580 T DE 3856580T DE 3856580 T DE3856580 T DE 3856580T DE 3856580 D1 DE3856580 D1 DE 3856580D1
Authority
DE
Germany
Prior art keywords
tissue factor
factor protein
production
deoxyribonucleic acid
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3856580T
Other languages
English (en)
Other versions
DE3856580T2 (de
Inventor
Richard Mark Lawn
Karen Lynne Wion
Gorden Allen Vehar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27359940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3856580(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE3856580D1 publication Critical patent/DE3856580D1/de
Application granted granted Critical
Publication of DE3856580T2 publication Critical patent/DE3856580T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
DE3856580T 1987-02-12 1988-02-12 Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein Expired - Lifetime DE3856580T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1374387A 1987-02-12 1987-02-12
US13743 1987-02-12
US3540987A 1987-04-07 1987-04-07
US35409 1987-04-07
US15269888A 1988-02-05 1988-02-05
US152698 1988-02-05

Publications (2)

Publication Number Publication Date
DE3856580D1 true DE3856580D1 (de) 2005-08-04
DE3856580T2 DE3856580T2 (de) 2006-05-24

Family

ID=27359940

Family Applications (3)

Application Number Title Priority Date Filing Date
DE0278776T Pending DE278776T1 (de) 1987-02-12 1988-02-12 Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein.
DE3856580T Expired - Lifetime DE3856580T2 (de) 1987-02-12 1988-02-12 Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein
DE3855921T Expired - Lifetime DE3855921T3 (de) 1987-02-12 1988-02-12 Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE0278776T Pending DE278776T1 (de) 1987-02-12 1988-02-12 Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3855921T Expired - Lifetime DE3855921T3 (de) 1987-02-12 1988-02-12 Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein

Country Status (10)

Country Link
EP (2) EP0787802B1 (de)
JP (1) JP2869920B2 (de)
AT (2) ATE298800T1 (de)
AU (1) AU617302B2 (de)
DE (3) DE278776T1 (de)
ES (2) ES2244989T3 (de)
GR (1) GR3024263T3 (de)
IE (1) IE81149B1 (de)
IL (1) IL85411A (de)
NZ (1) NZ223506A (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994988B1 (en) 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US7084251B1 (en) 1987-02-12 2006-08-01 Genentech, Inc. Methods and Deoxyribonucleic acid for the preparation of tissue factor protein
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
WO1988009817A1 (en) * 1987-06-12 1988-12-15 Mount Sinai School Of Medicine Of The City Univers Cloning and expression of human tissue factor
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington A method of inhibiting the isolation of a purer tissue factor
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DK299889A (da) * 1988-06-17 1989-12-18 Sinai School Medicine Kloning og ekspression af human vaevsfaktor
EP1201757A3 (de) * 1988-12-22 2002-09-11 Genentech, Inc. Verfahren zur Herstellung von wasserlöslichen Polypeptiden
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
EP0417298A4 (en) * 1989-02-02 1993-03-10 Teijin Limited Detection of human tissue factor activator
US5314695A (en) † 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
DE4240103A1 (de) * 1992-05-26 1993-12-02 Behringwerke Ag Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
ATE202633T1 (de) * 1994-04-28 2001-07-15 Dade Behring Inc Kalibrator für prothrombin-zeit-assays
US5696086A (en) * 1994-11-03 1997-12-09 Genentech, Inc. Methods and kits using macrophage stimulating protein
IL126383A0 (en) 1996-04-01 1999-05-09 Genentech Inc Apo-2li and apo-3 apoptosis polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6132729A (en) 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
US6642433B1 (en) 1997-05-15 2003-11-04 Trillium Therapeutics Inc. Fgl-2 knockout mice
WO1998051335A1 (en) * 1997-05-15 1998-11-19 Transplantation Technologies Inc. Methods of modulating immune coagulation
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
DE19749259A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
DE69904831T2 (de) 1998-07-13 2003-11-06 Univ Texas Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
PL354961A1 (en) 1999-10-01 2004-03-22 Chugai Seiyaku Kabushiki Kaisha Prevention and treatment of diseases associated with blood coagulation
EP1757701A1 (de) 1999-12-24 2007-02-28 Genentech, Inc. Verfahren und Zusammensetzungen zur Verlängerung der Halbzeiten der Entfernung von biowirksamen Verbindungen
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US7494782B2 (en) 2001-07-03 2009-02-24 Morrissey James H Assay for measuring factor viia-antithrombin complexes
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
EP1774001B1 (de) * 2004-06-25 2012-08-22 Altor BioScience Corporation Aus Pflanzen erhaltener Säugetier-spezifischer Gewebefaktor und dessen Anwendungen
US8623830B2 (en) 2006-09-12 2014-01-07 Beth Israel Deaconess Medical Center, Inc. Compositions containing α-1-antitrypsin and methods for use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663283A (en) 1980-03-24 1987-05-05 Genentech, Inc. Method of altering double-stranded DNA
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
NZ209307A (en) 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
US4680262A (en) 1984-10-05 1987-07-14 Genentech, Inc. Periplasmic protein recovery
WO1988009817A1 (en) * 1987-06-12 1988-12-15 Mount Sinai School Of Medicine Of The City Univers Cloning and expression of human tissue factor
DE10124940A1 (de) 2001-05-21 2002-11-28 Philips Corp Intellectual Pty Netzwerk mit logischen Kanälen und Transportkanälen

Also Published As

Publication number Publication date
GR3024263T3 (en) 1997-10-31
ES2068791T5 (es) 2004-12-16
EP0278776B2 (de) 2004-04-14
ES2244989T3 (es) 2005-12-16
ES2068791T1 (es) 1995-05-01
IE81149B1 (en) 2000-05-03
DE3855921D1 (de) 1997-07-03
JPS63301797A (ja) 1988-12-08
DE3856580T2 (de) 2006-05-24
EP0787802A3 (de) 1997-08-27
ES2068791T3 (es) 1997-10-01
IL85411A0 (en) 1988-07-31
DE3855921T3 (de) 2005-03-10
AU617302B2 (en) 1991-11-28
DE278776T1 (de) 1995-06-29
EP0787802A2 (de) 1997-08-06
ATE298800T1 (de) 2005-07-15
IE880380L (en) 1988-08-12
AU1170588A (en) 1988-08-18
EP0278776A2 (de) 1988-08-17
JP2869920B2 (ja) 1999-03-10
EP0278776A3 (de) 1989-09-13
EP0787802B1 (de) 2005-06-29
EP0278776B1 (de) 1997-05-28
NZ223506A (en) 1991-09-25
IL85411A (en) 1994-07-31
DE3855921T2 (de) 1998-01-15
ATE153696T1 (de) 1997-06-15

Similar Documents

Publication Publication Date Title
DE3855921D1 (de) Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein
ATE178616T1 (de) Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf)
DE68928934T2 (de) Verfahren zur herstellung von menschlicher dnase
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
LV10308A (lv) Ciliarais neirotropais faktors
BR9306670A (pt) Processo de separação de dnase humana dnase humana desamidada purificada composições farmacêuticas método de armazenamento de dnase humana e métodos de tratamento de paciente
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
ATE121100T1 (de) Ein neues thrombomodulin ähnliches glykoprotein erhältlich aus harn.
ATE124087T1 (de) Dna-sequenzen, rekombinante dna-moleküle und verfahren zur herstellung von lipocortin iii, iv, v, und vi.
DE3689977T2 (de) Dns-sequenzen, rekombinante dns-moleküle und verfahren zur herstellung menschlicher lipocortinähnlicher polypeptide.
HUT59724A (en) Process for producing new thrombosolving material
DE68919282D1 (de) Verfahren zur Herstellung von Cephalosporin und Zwischenverbindungen.
ATE208420T1 (de) Protein des cadherin-typs aus knochen und verfahren zur herstellung
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
KR910016339A (ko) Pp4-델타, 이의 제조방법 및 용도
ATE65543T1 (de) Dna-sequenzen des ebv-genoms, rekombinante dnamolek¨le, verfahren zur herstellung von ebvverwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
GR900100691A (el) Νευροτροφικός παράγοντας ακτινωτού.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition